First In Human Study of CX-801 in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Status
- RECRUITING
- Phase
- PHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
- Status
- COMPLETED
- Phase
- PHASE3
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
- Status
- RECRUITING
- Phase
- PHASE1
Patient Decision Aid Tool for HPV Vaccination Among Adults Ages 27-45 Years Old
- Status
- COMPLETED
- Phase
- NA
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Status
- RECRUITING
- Phase
- PHASE3
PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
- Status
- RECRUITING
- Phase
- PHASE3
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Status
- RECRUITING
- Phase
- PHASE3
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
- Status
- RECRUITING
- Phase
- N/A
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
- Status
- RECRUITING
- Phase
- N/A
The Impact of Community and Patient Engagement Practices on Vaccine Confidence in the United States
- Status
- NOT_YET_RECRUITING
- Phase
- N/A